EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

João Pedro Ferreira iD, Pedro Marques, Stefan D Anker, Javed Butler iD, Gerasimos Filippatos, Abhinav Sharma iD, Francisco Vasques-Nóvoa, Luís Mendonça iD, João Sérgio Neves, Milton Packer, Faiez Zannad

Diabetes, Obesity and Metabolism · 2026-02 · 28 (2) · 1105-1115

DOI: 10.1111/dom.70289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 10.11.2025. Verfasst von João Pedro Ferreira und 10 weiteren Autor:innen. Beteiligte Einrichtung: RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Albuminuria, Cardiovascular Diseases, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Boehringer Ingelheim, Eli Lilly.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co‐transporter 2 inhibitors ( SGLT2i ) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease ( CKD ). Patients with low‐ or without albuminuria have been underrepresented in randomised clinical trials ( RCTs ), and the effects of SGLT2i on cardiovascular and kidney outcomes across the full range of albuminuria require further investigation.

Aims

To study the effects of SGLT2i on kidney and cardiovascular outcomes across albuminuria levels in populations with different cardiovascular–kidney–metabolic ( CKM ) risk.

Methods

Individual‐patient data pooled analysis of RCTs across the CKM spectrum. Outcomes were studied across urinary albumin‐to‐creatinine ratio ( UACR ) both as categorical and continuous variables using survival and mixed effects models.

Results

A total of 26 750 patients were included. The median (pct 25‐75 ) baseline UACR was 28 (8–240) mg/g: 13 669 (51.1%) had UACR 300 mg/g. Compared to patients with lower UACR , those with higher UACR were younger, with a more frequent history of hypertension, diabetes, and obesity, and lower eGFR . UACR was linearly associated with kidney and cardiovascular outcomes as well as mortality. Compared to placebo, SGLT2i reduced the risk of kidney events, HF hospitalisations, atherothrombotic events, cardiovascular and all‐cause mortality across the full UACR spectrum (Pinteraction >0.1 for all outcomes). Compared to placebo, SGLT2i reduced albuminuria levels by 13%, on average: gMratio 0.87, 95% CI 0.85–0.88, p < 0.001.

Conclusions

Higher albuminuria was associated with an increased risk of cardiovascular and kidney outcomes. SGLT2i improved cardiovascular and kidney outcomes across the full range of albuminuria, including normo‐albuminuria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsAlbuminuriaCardiovascular DiseasesRenal Insufficiency, ChronicDiabetes Mellitus, Type 2Diabetic NephropathiesHumansRandomized Controlled Trials as TopicMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

albuminuriacardiovascular–kidney–metabolickidney outcomessodium glucose co‐transported 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
  • Université de Lorraine, INSERM, Centre d'Investigations Cliniques, CHRU de Nancy, Inserm and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Nancy, France.
  • Serviço de Medicina Interna, Unidade Local de Saúde São João, Porto, Portugal.
  • Department of Cardiology (CVK) of German Heart Center Charité, German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.
  • Baylor Scott and White Research Institute, Dallas, TX and University of Mississippi, Jackson, Mississippi, USA.
  • National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.

ORCID-Profile: João Pedro Ferreira, Javed Butler, Abhinav Sharma, Luís Mendonça

Förderung

  • CIHR
  • Boehringer Ingelheim
  • Eli Lilly
  • Janssen Research and Development
  • Canadian Institutes of Health Research

Zitieren

APA

Ferreira, J. P., Marques, P., Anker, S. D., Butler, J., Filippatos, G., Sharma, A., Vasques-Nóvoa, F., Mendonça, L., Neves, J. S., Packer, M., & Zannad, F. (2026). Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials. Diabetes, Obesity and Metabolism, 28(2), 1105-1115. https://doi.org/10.1111/dom.70289

Vancouver

Ferreira JP, Marques P, Anker SD, Butler J, Filippatos G, Sharma A, et al. Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials. Diabetes, Obesity and Metabolism. 2026;28(2):1105-1115. doi:10.1111/dom.70289

BibTeX
@article{Ferreira2026,
  author = {Ferreira, João Pedro and Marques, Pedro and Anker, Stefan D and Butler, Javed and Filippatos, Gerasimos and Sharma, Abhinav and Vasques-Nóvoa, Francisco and Mendonça, Luís and Neves, João Sérgio and Packer, Milton and Zannad, Faiez},
  title = {Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {2},
  pages = {1105--1115},
  doi = {10.1111/dom.70289}
}
Kostenlos starten →